Fireside Chat: The Viscogliosi Brothers Journey, and What's Next?

Join moderator Brandon Bendes in conversation with John Viscogliosi from Viscogliosi Bros, exploring the brothers’ entrepreneurial journey in medtech and their vision for the future. For more information watch this video https://www.youtube.com/watch?v=VjI2xPsGmF0&t=81s 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Teleflex’s Acquisition of BIOTRONIK’s Vascular Business and Intent to Split into Two Entities

The medtech industry witnessed another significant shift in February 2025 as Teleflex made two major announcements that have the potential to reshape its future. On February 27th, Teleflex revealed plans to divide into two separate publicly traded entities, each focusing on different aspects of the business. In addition, the company announced that it would acquire BIOTRONIK’s vascular intervention business for approximately $791 million. This strategic move underscores Teleflex’s commitment to expanding its footprint in the vascular market. As Teleflex transitions into this new phase, the focus shifts to understanding what this acquisition means for the company’s growth and the broader  spinal cord stimulation market . The decision to integrate BIOTRONIK’s vascular intervention portfolio further strengthens Teleflex’s presence in the vascular access and interventional fields. But what does this deal signal about the company’s future and the landscape of the vascular market? In this...
Read more